(Q27027876)

Peter F Bross

2

1 reference

Ke Liu

3

1 reference

Marc Theoret

4

1 reference

Angelo R De Claro

5

1 reference

Jinhua Lu

6

1 reference

Whitney Helms

7

1 reference

Brian Niland

8

1 reference

Syed R Husain

9

1 reference

Raj K Puri

10

1 reference

language of work or name

1 reference

2013

1 reference

Journal for Immunotherapy of Cancer

published in

1 reference

volume

1

1 reference

page(s)

5

1 reference

https://scigraph.springernature.com/pub.10.1186/2051-1426-1-5

exact match

0 references

cites work

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

Adoptive immunotherapy for cancer: harnessing the T cell response

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

Cancer immunotherapy comes of age

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

The mechanism of action of MF59 - an innately attractive adjuvant formulation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986979

Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research

28 September 2017

1 reference

12 December 2020

Investigation of porcine circovirus contamination in human vaccines

1 reference

12 December 2020

International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice

1 reference

12 December 2020

Immunotherapy for bladder cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/2051-1426-1-5

1 reference